Brief: Zymeworks Gets FDA OK for IND on ZW251, a Novel GPC3-Targeted Topoisomerase 1 ADC
28/07/2025 11:07
July 28 (Reuters) - Zymeworks Inc ZYME.O: ZYMEWORKS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ZW251, A NOVEL GLYPICAN 3-TARGETED TOPOISOMERASE 1 INHIBITOR ANTIBODY-DRUG CONJUGATE ZYMEWORKS INC - PHASE 1 TRIAL FOR ZW251 IN HCC EXPECTED IN 2025 Source text: ID:nGNXgZtB8 Further company coverage: ZYME.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zymeworks
See all newsUS STOCKS ON THE MOVE-Huron Consulting, RingCentral, Selective Insurance
U.S. STOCKS ON THE MOVE-Huron Consulting, Crown Castle, Bloom Energy
US STOCKS ON THE MOVE-Booz Allen Hamilton, SLB, Deckers Outdoor
US STOCKS ON THE MOVE-American Express, Gorman-Rupp, Moderna
Zymeworks gains on up to $813 million Roche licensing deal for lung cancer drug